# Phytosterols Cholesterol Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/phytosterols-cholesterol-meta-analysis-evidence-review
Category: evidence-review
Summary: Phytosterols Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are 
Last reviewed: 2026-06-24
Reviewed by: Migaku Evidence Review
# Phytosterols Cholesterol Meta-analysis: What the Evidence Says

## Quick Answer

Phytosterols Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The Mediterranean Diet and Cerebrovascular Risk Factors: A Lifeline for Vascular Health-Narrative Review. | preclinical study | 4 | 2026-04-17 | 10.3390/nu18081273 |
| Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols. | preclinical study | 4 | 2025-10-21 | 10.1007/s11883-025-01334-7 |

## What The Sources Report

- Consequently, healthcare initiatives worldwide are placing greater emphasis on preventing and lowering cerebrovascular risk. [Pacinella G (2026); evidence level 4]
- Alongside medical therapies, it is now widely recognized that modifying risk factors-many of which are controllable-can substantially reduce the probability of acute cerebrovascular events, up to 33% according to data from trials such as PREDIMED. [Pacinella G (2026); evidence level 4]
- Two key issues remain: despite extensive research, the etiology of premature atherosclerosis in sitosterolemia is still uncertain, and discussion of phytosterol atherogenicity has not been grounded in quantitative evidence, hindering true risk assessment. [Nakano T (2025); evidence level 4]
- Although ABCG5/G8-deficient animal models recapitulate the symptoms of sitosterolemia, including hematologic abnormalities and organ dysfunction, increased atherogenicity has not been observed in these models. [Nakano T (2025); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For phytosterols cholesterol meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Pacinella G (2026). The Mediterranean Diet and Cerebrovascular Risk Factors: A Lifeline for Vascular Health-Narrative Review.. DOI: 10.3390/nu18081273. PMCID: PMC13119117. PMID: 42075087. https://pmc.ncbi.nlm.nih.gov/articles/PMC13119117/
- Nakano T (2025). Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols.. DOI: 10.1007/s11883-025-01334-7. PMCID: PMC12540574. PMID: 41118071. https://pmc.ncbi.nlm.nih.gov/articles/PMC12540574/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.